Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
New Leaf Venture Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
New Leaf Venture Partners

New Leaf Venture Partners

Operating

New Leaf Venture Partners, a NY-based VC firm, invests in biopharma, IT, medical devices, and bio-research.

Location
New York City, NY, US
Founded
2005
Firm
Compare
Portfolio
Employees
Website

New Leaf Venture Partners, based in New York, is a venture capital firm that focuses on investments in the biopharmaceutical, information technology, medical devices, and biological research sectors. The firm typically engages in Series A through Series E funding rounds, with a notable presence in Series B and C stages. Their geographical focus includes both New York and California, supporting companies that are driving innovation in healthcare.

The firm's portfolio includes prominent companies such as AiCure, Alector, Aptinyx, and Braeburn. Key partners at New Leaf Venture Partners bring extensive industry experience and networks to the table, enhancing their investment strategy. The firm emphasizes a hands-on approach, offering strategic guidance and leveraging their deep sector expertise to add value beyond capital. This commitment to active partnership helps their portfolio companies navigate growth challenges and achieve significant milestones.

New Leaf Venture Partners - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments92
Current Portfolio Count40
Total Portfolio Exits5

Top Investment Stages

Series B21 (29.2%)
Series Unknown19 (26.4%)
Series C14 (19.4%)
Series A12 (16.7%)
Series D6 (8.3%)

Stage Mix

Series B 29%Series Unknown 26%Series C 19%Series A 17%Series D 8%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Arvist logo

Arvist

Star Therapeutics logo

Star Therapeutics

Arine logo

Arine

Electra Therapeutics logo

Electra Therapeutics

Asimily logo

Asimily

Cleerly logo

Cleerly

BrightInsight logo

BrightInsight

TigerConnect logo

TigerConnect

AiCure logo

AiCure

Qlaris Bio logo

Qlaris Bio

CuraSen Therapeutics logo

CuraSen Therapeutics

Alector logo

Alector

Neurana Pharmaceuticals logo

Neurana Pharmaceuticals

Kyruus logo

Kyruus

Arvinas logo

Arvinas

Braeburn logo

Braeburn

Aptinyx logo

Aptinyx

Truveris logo

Truveris

Neuronetics logo

Neuronetics

Deciphera Pharmaceuticals logo

Deciphera Pharmaceuticals

Wave Life Sciences logo

Wave Life Sciences

Cogent Biosciences logo

Cogent Biosciences

Cardiokinetix logo

Cardiokinetix

Intarcia Therapeutics logo

Intarcia Therapeutics

Catalyst Pharmaceuticals logo

Catalyst Pharmaceuticals

New Leaf Venture Partners - Classification

Also Known As
  • New Leaf Venture Partners, L.L.C.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 12 more industry codes
NAICS
  • 522200Nondepository Credit Intermediation
  • 522220Sales Financing
  • 522000Credit Intermediation and Related Activities
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6100Nondepository Credit Institutions
  • 6140Personal Credit Institutions
  • 6141Personal Credit Institutions
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end